Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label multicenter study of zanubrutinib plus rituximab in hairy cell leukemia
MOH_2025-05-18_014099Phase 2Not yet recruiting
- Sponsor
- פרופ' תמר תדמור
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib and rituximab in hairy cell leukemia (HCL) and Hairy cell leukemia variant (HCL-V), sponsored by פרופ' תמר תדמור. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
zanubrutinibrituximab
03
Conditions
hairy cell leukemia (HCL)Hairy cell leukemia variant (HCL-V)
Beyond the preview
Go deeper on MOH_2025-05-18_014099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-18_014099.